Table 1.
Liposome-based miRNA delivery used their therapeutic effect
| Cell lines | Loaded therapeutic agent | Biological effect | Molecular changes | References |
|---|---|---|---|---|
| Hepa1c1c7 | antimiR-122 | Improved intratumor accumulation | Up-regulation of ALDOA, BCKDK, NDRG3 | [48] |
| HUVECs,26 NL-17 | miR-499 | Anti-angiogenic, improved intratumor accumulation, small tumor volume | Down-regulation of FZD8, CnAα,VEGFA | [53] |
| CRL-2081, CRL-5830, A549 | let-7a | Increased cellular uptake, reduced proliferation and invasion, small tumor volume | Down-regulation of H-RAS, N-RAS and K-RAS | [42] |
| HepG2 | antimiR-221 | No effect on cell proliferation, increased apoptosis, cell cycle arrest | Up-regulation of PTEN, P27kip1, TIMP3 | [49] |
| HepG2, Hep3B | miR-375 cisplatin | Decreased viability, increased apoptosis and cell cycle arrest, small tumor size, accumulation in the liver, kidney and tumor | NA | [50] |
| A549 | antimiR-21 paclitaxel | Decreased viability (paclitaxel), decreased invasion/migration, small tumor size | Up-regulation of PTEN, PDCD4, RECK, TIMP3, ANKRD46 DDAH1 | [54] |
| CNE1, CNE2, SUNE1, H0NE1, 5-8F, 6-10B C666-1 | miR-124-3p | Decreased proliferation, invasion/migration, no effect on apoptosis | Down-regulation of STAT3, CCND2, MMP-2 | [55] |
| SMMC-7721, Huh7 and HepG2 cell | miR-101 | Decreased invasion/migration colony formation, increased apoptosis, small tumor size | Down-regulation of NLK, EZH2, MCL-1, STMN1, RAB5A | [51] |
| MCF-7, ZR-75-1, L929 | antimiR-191 | Decreased viability, increased cell death, decreased tumorigenicity and migration | NA | [56] |